BIOGEN INC. Excess Tax Benefit from Share-based Compensation, Financing Activities
BIOGEN INC. (BIIB) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $12.60 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-02.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2017-02-02
- BIOGEN INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was $700.00K, a 90.54% decline year-over-year.
- BIOGEN INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was $2.90M, a 163.64% increase year-over-year.
- BIOGEN INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-06-30 was $700.00K, a 78.79% decline year-over-year.
- BIOGEN INC. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-03-31 was $8.30M, a 87.50% decline year-over-year.
- BIOGEN INC. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $12.60M, a 83.89% decline from fiscal 2015.
- BIOGEN INC. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $78.20M, a 18.88% decline from fiscal 2014.
- BIOGEN INC. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $96.40M, a 31.16% increase from fiscal 2013.
- BIOGEN INC. excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $73.50M, a 34.28% increase from fiscal 2012.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $3.60M derived: sum of 2 quarters · filed 2017-02-02 | $4.30M derived: sum of 3 quarters · filed 2017-02-02 | $12.60M 10-K · filed 2017-02-02 | ||||
| 2016-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $3.60M derived: sum of 2 quarters · filed 2016-10-26 | $11.90M 10-Q · filed 2016-10-26 | $19.30M derived: sum of 4 quarters · filed 2017-02-02 | ||||
| 2016-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21 | $9.00M 10-Q · filed 2016-07-21 | $16.40M derived: sum of 3 quarters · filed 2017-02-02 | $17.50M derived: sum of 4 quarters · filed 2017-02-02 | ||||
| 2016-03-31 | $8.30M 10-Q · filed 2016-04-21 | $15.70M derived: sum of 2 quarters · filed 2017-02-02 | $16.80M derived: sum of 3 quarters · filed 2017-02-02 | $20.10M derived: sum of 4 quarters · filed 2017-02-02 | ||||
| 2015-12-31 | $7.40M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $8.50M derived: sum of 2 quarters · filed 2017-02-02 | $11.80M derived: sum of 3 quarters · filed 2017-02-02 | $78.20M 10-K · filed 2017-02-02 | ||||
| 2015-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $4.40M derived: sum of 2 quarters · filed 2016-10-26 | $70.80M 10-Q · filed 2016-10-26 | $70.78M 10-Q · filed 2015-10-21 | $76.78M derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2015-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21 | $69.70M 10-Q · filed 2016-07-21 | $69.69M 10-Q · filed 2015-07-24 | $75.68M derived: sum of 3 quarters · filed 2017-02-02 | $82.16M derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2015-03-31 | $66.40M 10-Q · filed 2016-04-21 | $66.43M 10-Q · filed 2015-04-24 | $72.38M derived: sum of 2 quarters · filed 2017-02-02 | $78.86M derived: sum of 3 quarters · filed 2017-02-02 | $83.34M derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2014-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $12.46M derived: sum of 2 quarters · filed 2017-02-02 | $16.94M derived: sum of 3 quarters · filed 2017-02-02 | $96.40M 10-K · filed 2017-02-02 | $96.38M 10-K · filed 2015-02-04 | |||
| 2014-09-30 | $6.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-21 | $10.97M derived: sum of 2 quarters · filed 2015-10-21 | $90.42M 10-Q · filed 2015-10-21 | $96.02M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-06-30 | $4.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-24 | $83.94M 10-Q · filed 2015-07-24 | $89.54M derived: sum of 3 quarters · filed 2016-02-03 | $104.13M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-03-31 | $79.46M 10-Q · filed 2015-04-24 | $85.05M derived: sum of 2 quarters · filed 2016-02-03 | $99.64M derived: sum of 3 quarters · filed 2016-02-03 | $115.56M derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2013-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $20.19M derived: sum of 2 quarters · filed 2016-02-03 | $36.10M derived: sum of 3 quarters · filed 2016-02-03 | $73.50M 10-K · filed 2016-02-03 | $73.47M 10-K · filed 2014-02-06 | |||
| 2013-09-30 | $14.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-22 | $30.50M derived: sum of 2 quarters · filed 2014-10-22 | $67.90M 10-Q · filed 2014-10-22 | |||||
| 2013-06-30 | $15.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-23 | $53.31M 10-Q · filed 2014-07-23 | ||||||
| 2013-03-31 | $37.40M 10-Q · filed 2014-04-23 | |||||||
| 2012-12-31 | $54.74M 10-K · filed 2015-02-04 | |||||||
| 2011-12-31 | $7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $12.76M derived: sum of 2 quarters · filed 2014-02-06 | $40.53M derived: sum of 3 quarters · filed 2014-02-06 | $50.59M 10-K · filed 2014-02-06 | ||||
| 2011-09-30 | $5.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $33.48M derived: sum of 2 quarters · filed 2011-10-28 | $43.55M 10-Q · filed 2011-10-28 | $50.40M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-06-30 | $27.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $37.83M 10-Q · filed 2011-07-26 | $44.68M derived: sum of 3 quarters · filed 2013-02-05 | $45.37M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2011-03-31 | $10.06M 10-Q · filed 2011-04-21 | $16.91M derived: sum of 2 quarters · filed 2013-02-05 | $17.60M derived: sum of 3 quarters · filed 2013-02-05 | $18.82M derived: sum of 4 quarters · filed 2013-02-05 | ||||
| 2010-12-31 | $6.85M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $7.54M derived: sum of 2 quarters · filed 2013-02-05 | $8.76M derived: sum of 3 quarters · filed 2013-02-05 | $13.14M 10-K · filed 2013-02-05 | ||||
| 2010-09-30 | $686.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $1.91M derived: sum of 2 quarters · filed 2011-10-28 | $6.28M 10-Q · filed 2011-10-28 | $6.53M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $5.60M 10-Q · filed 2011-07-26 | $5.84M derived: sum of 3 quarters · filed 2012-02-03 | $6.23M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2010-03-31 | $4.38M 10-Q · filed 2011-04-21 | $4.62M derived: sum of 2 quarters · filed 2012-02-03 | $5.01M derived: sum of 3 quarters · filed 2012-02-03 | $5.53M derived: sum of 4 quarters · filed 2012-02-03 | ||||
| 2009-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $636.00K derived: sum of 2 quarters · filed 2012-02-03 | $1.15M derived: sum of 3 quarters · filed 2012-02-03 | $3.44M 10-K · filed 2012-02-03 | ||||
| 2009-09-30 | $394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $912.00K derived: sum of 2 quarters · filed 2010-10-26 | $3.19M 10-Q · filed 2010-10-26 | $3.76M derived: sum of 4 quarters · filed 2011-02-04 | ||||
| 2009-06-30 | $518.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $2.80M 10-Q · filed 2010-07-20 | $3.37M derived: sum of 3 quarters · filed 2011-02-04 | $12.34M derived: sum of 4 quarters · filed 2011-02-04 | ||||
| 2009-03-31 | $2.28M 10-Q · filed 2010-04-20 | $2.85M derived: sum of 2 quarters · filed 2011-02-04 | $11.82M derived: sum of 3 quarters · filed 2011-02-04 | |||||
| 2008-12-31 | $566.00K derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $9.54M derived: sum of 2 quarters · filed 2011-02-04 | $27.99M 10-K · filed 2011-02-04 | |||||
| 2008-09-30 | $8.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | $27.42M 10-Q · filed 2009-10-21 | ||||||
| 2008-06-30 | $18.45M 10-Q · filed 2009-07-17 | |||||||
| 2007-12-31 | $69.67M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |